Reduced Folate Carrier Protein Expression in Osteosarcoma: Implications for the Prediction of Tumor Chemosensitivity

Cancer

Volumn 98, Issue 9, 2003, Pages 1958-1966

  Ifergan, Ilan ^a   Meller, Issac ^b   Issakov, Josefin ^b   Assaraf, Yehuda G ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemosensitivity; Chemotherapy; Drug transport; High dose methotrexate; Multidrug resistance protein 1; Osteosarcoma; Reduced folate carrier; Western blot analysis

Indexed keywords

ABC TRANSPORTER; BETA ACTIN; CARRIER PROTEIN; DIHYDROFOLATE REDUCTASE; FOLIC ACID; FOLINIC ACID; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; REDUCED FOLATE CARRIER;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OSTEOSARCOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR RECURRENCE; WESTERN BLOTTING;

ACTINS; ADOLESCENT; ADULT; BONE NEOPLASMS; CARRIER PROTEINS; CHILD; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0142150087     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11741     Document Type: Article

References (47)

1. Malawer MM, Link MP, Donaldson SS. In: De Vita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology (5th edition). Volume 2. New York: Lippincott-Raven, 1997:1789-1852.
2. Wittig JC, Bickels J, Priebat D, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123-1132.
3. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop. 2002;397:40-52.
4. Jaffe N, Frei E, Watts H, et al. High-dose methotrexate in osteosarcoma: a 5-year experience. Cancer Treat Rep. 1978; 62:259-264.
5. Saeter G, Alvegard TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high dose-methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991;9:1766-1775.
6. Meyers PA, Heller G, Healey JH, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
7. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: the results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-2458.
8. Ferrari S, Sassoli V, Orlandi M, et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother. 1993;5:135-141.
9. Delepine N, Delepine G, Bacci G, et al. Influence of methotrexate dose intensity on outcome of patients with high-grade osteogenic sarcoma. Cancer. 1996;78:2127-2135.
10. Leung S, Marshall GM, Al Mahr M, et al. Prognostic significance of chemotherapy dose characteristic in children with osteogenic sarcoma. Med Pediatr Oncol. 1997;28:179-182.
11. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.
12. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 1999; 5:621-627.
13. Assaraf YG, Rothem L, Hooijberg JH, et al. Loss of multidrug resistance protein 1 (MRP1) expression and folate efflux activity results in a highly concentrative transport of folates in human leukemia cells. J Biol Chem. 2003;278:6680-6686.
14. Jansen G. Receptor- and carrier-mediated transport systems for folates and antifolates: exploitation for folate-based chemotherapy and immunotherapy. In: Jackman AL, editor. Antifolate drugs in cancer therapy. Totowa, NJ: Humana Press, 1999:293-321.
15. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001;61:7225-7232.
16. Bertino JR. Ode to methotrexate. J Clin Oncol. 1993;11:5-14.
17. Goldman ID. Membrane transport of chemotherapeutics and drug resistance: beyond the ABC family of exporters to the role of carrier-mediated processes. Clin Cancer Res. 2002;8:4-6.
18. Borst P, Oude Elferink R. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537-592.
19. Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59:2532-2535.
20. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A. 1999;96:6914-6919.
21. Zeng H, Bain IJ, Belinsky MG, et al. Expression of multidrug resistance protein 3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer drugs. Cancer Res. 1999;59:5964-5967.
22. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance pattern in transfected NIH3T3 cells. J Natl Cancer Inst. 2000;92:1934-1940.
23. Volk EL, Farley KM, Wu Y, et al. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 2002;62:5035-5040.
24. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1560-1564.
25. Gong M, Yess J, Connolly T, et al. Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Blood. 1997;89:2494-2499.
26. Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem. 1998;273:30189-30198.
27. Wong S, Zhang L, Witt TL, et al. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem. 1999;274:10388-10394.
28. Drori S, Jansen G, Mauritz R, et al. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem. 2000;275:30855-30863.
29. Rothem L, Ifergan I, Kaufman Y, et al. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem J. 2002; 367:741-750.
30. Rothem L, Aronheim A, Assaraf YG. Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem. 2003;278:8935-8941.
31. Zhao R, Sharina IG, Goldman ID. Pattern of mutations that results in loss of a reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol Pharmacol. 1999;56:68-76.
32. Goker E, Waltham M, Kheradpour A, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood. 1995;86:677-684.
33. Matherly LH, Taub JW, Ravindranath Y, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements of methotrexate resistance in childhood acute lymphoblastic leukemia. Blood. 1995;85:500-509.
34. Gorlick R, Goker E, Trippet T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood. 1996;89: 1013-1018.
35. Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute lymphoblastic leukemia. N Engl J Med. 1996;335:1041-1048.
36. Jansen G, Westerhof GR, Jarmuszewski MJ, et al. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier: selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J Biol Chem. 1990;265:18272-18277.
37. Tomer G, Cohen IJ, Kidron D, et al. Prognostic factors in non-mestastatic limb osteosarcoma: a 20-year experience of one center. Int J Oncol. 1999;15:179-185.
38. Huvos AG. In: Huvos AG. Bone tumors: diagnosis, treatment and prognosis, 2nd edition. Philadelphia: W.B. Saunders, 1991:122-128.
39. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma. Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch Pathol Lab Med. 1997;101:14-18.
40. Rosen G, Capparos B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of post-operative adjuvant based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49: 1221-1230.
41. Cole PD, Smith AK, Kamen BA. Osteosarcoma cells, resistant to methotrexate due to nucleotide and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol. 2002;50:111-116.
42. Worm J, Kirkin AF, Dzhandzhugazyan KN, et al. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem. 2001;276:39990-40000.
43. Sczesny F, Hempel G, Boos J, et al. Capillary electrophoretic drug monitoring of methotrexate and leucovorin and their metabolites. J Chromatogr B Biomed Sci Appl. 1998;718:177-185.
44. De Graaf D, Sharma RC, Mechetner EB, et al. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci U S A. 1996;93:1238-1242.
45. Yang R, Sowers R, Mazza B, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma samples. Clin Cancer Res. 2003;9:837-844.
46. Zhao R, Assaraf YG, Goldman ID. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem. 1998;273:7873-7879.
47. Aggarwal S, Gupta S. A possible role for multidrug resistance-associated protein in the secretion of basic fibroblast growth factor by osteogenic sarcoma cell line (MG-63). Int J Oncol. 1998;13:1331-1334.